Literature DB >> 19076381

Opportunities and challenges in the discovery of new central nervous system drugs.

James E Krause1, Bertrand L Chenard.   

Abstract

There have been relatively few new mechanism-based approvals for nervous system relevant drugs over the past 5 years, despite the increasing budgets of pharmaceutical and biotechnology companies. The genomic revolution has provided scientists with many molecular targets for drug discovery and research advances in chemistry, drug metabolism, pharmacology, and toxicology have provided much insight into understanding the pitfalls of the drug discovery and development process. Herein is provided a perspective on both the opportunities and challenges in the discovery and development of novel medicines for the treatment of human CNS disorders.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19076381     DOI: 10.1196/annals.1418.024

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  2 in total

1.  Proteomics for Target Identification in Psychiatric and Neurodegenerative Disorders.

Authors:  André S L M Antunes; Valéria de Almeida; Fernanda Crunfli; Victor C Carregari; Daniel Martins-de-Souza
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  Advances in microRNA experimental approaches to study physiological regulation of gene products implicated in CNS disorders.

Authors:  Justin M Long; Debomoy K Lahiri
Journal:  Exp Neurol       Date:  2012-01-05       Impact factor: 5.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.